Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
In a recent study published in Emerging Infectious Diseases, researchers reported natural reassortment of influenza viruses in pigs.
Researchers explored the effectiveness of Ginkgo biloba L. folium extract (EGb) in the management of COVID-19 severity.
Researchers performed a quantitative assessment of the age-stratified seroprevalence of hemagglutination inhibition antibodies against five swine influenza viruses circulating in the Guangzhou and Hong Kong cities of China.
Researchers create a vaccine candidate that could protect against both SARS-CoV-2 and IAVs.
A new study investigated the effect of low circulating seasonal influenza virus during the SARS-CoV-2 pandemic on the antibody titers against influenza during the same period.
A new study investigates whether the proportion of ribosomal genes displaying differential gene expression and differential alternative splicing differed between three betacoronaviruses and six other viruses and bacteria.
A new review identified clinical studies evaluating coronavirus infections in the context of Echinacea administration and assessed preventive and therapy advantages against COVID-19.
A recent report explores the dynamics of viral interference between various respiratory viruses in light of the ongoing COVID-19 pandemic.
A new CDC study published in the journal Clinical Infectious Diseases (CID) shows that flu vaccination protected children against serious flu illness even when they were infected with a flu virus that was antigenically different from the vaccine virus.
Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.
A recent review article looks at the potential of nanotechnology in fighting severe acute respiratory syndrome 2 (SARS-CoV-2), with several possibilities of strategies in therapeutics, vaccines, and prevention.
A new study, published on the bioRxiv* preprint server, has discovered a class of new immunostimulatory RNAs while studying influenza infection-associated host genes in human lung epithelial cells using small interfering RNAs (siRNAs). Scientists revealed that these short duplex RNAs could induce type I and type III interferons (IFN-I/III) in a wide variety of cells.
Researchers evaluate the safety and immunogenicity of an influenza vaccine and mRNA-based COVID-19 vaccine that were administered concomitantly.
German scientists used DNA nanolevers to target the interaction between a peptide known as PeB and influenza A.
A new study demonstrates the influence of prior infectious outbreaks in a large population on succeeding pandemic outcomes.
The COVID-19 vaccine is currently the best form of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. But a new perspective article published in the journal PNAS suggests it’s not the panacea to stopping SARS-CoV-2.
According to research from the University of California, some cases of severe coronavirus disease 2019 (COVID-19) may be related to the immunological memory of previous H3N2 influenza A infection.
Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.
In a recent study, researchers demonstrated a human organ-on-a-chip (Organ Chip) microfluidic model of the lung alveolus (Alveolus Chip) - that recapitulates the human alveolar-capillary interface with an air-liquid interface (ALI) and vascular fluid flow to understand the local triggers in the lung in vitro.
The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research.